Chronic Acquired Demyelinating Polyneuropathies

ABSTRACT

Several entities can be put under the heading of chronic acquired demyelinating polyneuropathy. Future research will hopefully provide a greater understanding of pathophysiology, which may suggest the ideal way to classify and manage these patients. In the meantime, it is reasonable and useful to use clinical, laboratory, and electrodiagnostic data to classify patients in ways that facilitate identification and treatment. This article outlines an approach to the diagnosis and management of chronic acquired demyelinating polyneuropathies.

KEYWORDS

Chronic acquired demyelinating polyneuropathy - chronic inflammatory demyelinating polyradiculoneuropathy - CIDP

REFERENCES

• 1 Dyck P J, Lais A C, Ohta M, Bastron J A, Okazaki H, Groover R V. Chronic inflammatory polyradiculoneuropathy.  Mayo Clin Proc. 1975;  50 621-637
• 2 Barohn R J, Kissel J T, Warmolts J R, Mendell J R. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria.  Arch Neurol. 1989;  46 878-884
• 3 Katz J S, Saperstein D S, Gronseth G S, Amato A A, Barohn R J. Distal acquired demyelinating symmetrical neuropathy.  Neurology. 2000;  54 615-620
• 4 Barohn R J, Saperstein D S. Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy.  Semin Neurol. 1998;  18 49-61
• 5 Hattori N, Misu K, Koike H et al.. Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy.  J Neurol Sci. 2001;  184 57-63
• 6 Gorson K C, Allam G, Ropper A H. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy.  Neurology. 1997;  48 321-328
• 7 Sabatelli M, Madia F, Mignogna T, Lippi G, Quaranta L, Tonali P. Pure motor chronic inflammatory demyelinating polyneuropathy.  J Neurol. 2001;  248 772-777
• 8 Sakakibara R, Hattori T, Kuwabara S et al.. Micturitional disturbance in patients with chronic inflammatory demyelinating polyneuropathy.  Neurology. 1998;  50 1179-1182
• 9 Prineas J W, McLeod J R. Chronic relapsing polyneuritis.  J Neurol Sci. 1976;  27 427-458
• 10 van der Meche F G, van Doorn P A. Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy: immune mechanisms and update on current therapies.  Ann Neurol. 1995;  37(S1) S14-S31
• 11 Hughes R, Sanders E, Hall S, Atkinson P, Colchester A, Payan P. Subacute idiopathic demyelinating polyradiculoneuropathy.  Arch Neurol. 1992;  49 612-616
• 12 Oh S J. Subacute demyelinating polyneuropathy responding to corticosteroid treatment.  Arch Neurol. 1978;  35 509-516
• 13 Dalakas M C, Houff S A, Engel W K, Madden D L, Sever J L. CSF “monoclonal” bands in chronic relapsing polyneuropathy.  Neurology. 1980;  30 864-867
• 14 Molenaar D S, Vermeulen M, de Haan R. Diagnostic value of sural nerve biopsy in chronic inflammatory demyelinating polyneuropathy.  J Neurol Neurosurg Psychiatry. 1998;  64 84-89
• 15 Bosboom W M, Van den Berg L H, Franssen H et al.. Diagnostic value of sural demyelination in chronic inflammatory demyelinating polyneuropathy.  Brain. 2001;  124 2427-2438
• 16 Bouchard C, Lacroix C, Plante V et al.. Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy.  Neurology. 1999;  52 498-503
• 17 Cornblath D R, Griffin D E, Welch D, Griffin J W, McArthur J C. Quantitative analysis of endoneurial T-cells in human sural nerve biopsies.  J Neuroimmunol. 1990;  26 113-118
• 18 Matsumuro K, Izumo S, Umehara F, Osame M. Chronic inflammatory demyelinating polyneuropathy: histological and immunopathological studies in biopsied sural nerves.  J Neurol Sci. 1994;  127 170-178
• 19 Bosboom W M, Van den Berg L H, De Boer L et al.. The diagnostic value of sural nerve T cells in chronic inflammatory demyelinating polyneuropathy.  Neurology. 1999;  53 837-845
• 20 Bosboom W M, van den Berg L H, Franssen H et al.. Diagnostic value of sural nerve demyelination in chronic inflammatory demyelinating polyneuropathy.  Brain. 2001;  124 2427-2438
• 21 Vallat J M, Tabaraud F, Magy L et al.. Diagnostic value of nerve biopsy for atypical chronic inflammatory demyelinating polyneuropathy: evaluation of eight cases.  Muscle Nerve. 2003;  27 478-485
• 22 Boukhris S, Magy L, Kabore R et al.. Atypical electrophysiologic findings in chronic inflammatory demyelinating polyneuropathy (CIDP)-diagnosis confirmed by nerve biopsy.  Neurophysiol Clin. 2004;  34 71-79
• 23 Chin R L, Latov N, Sander H W et al.. Sensory CIDP presenting as cryptogenic sensory polyneuropathy.  J Peripher Nerv Syst. 2004;  9 132-137
• 24 Rajabally Y A, Jacob S, Abbott R J. Clinical heterogeneity in mild chronic inflammatory demyelinating polyneuropathy.  Eur J Neurol. 2006;  13 958-962
• 25 Austin J H. Recurrent polyneuropathies and their corticosteroid treatment.  Brain. 1958;  81 157-194
• 26 Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force . Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force.  Neurology. 1991;  41 617-618
• 27 Bromberg M B. Comparison of electrodiagnostic criteria for primary demyelination in chronic polyneuropathy.  Muscle Nerve. 1991;  14 968-976
• 28 Thaisetthawatkul P, Logigian E L, Herrmann D N. Dispersion of the distal compound muscle action potential as a diagnostic criterion for chronic inflammatory demyelinating polyneuropathy.  Neurology. 2002;  59 1526-1532
• 29 Magda P, Latov N, Brannagan III T H, Weimer L H, Chin R L, Sander H W. Comparison of electrodiagnostic abnormalities and criteria in a cohort of patients with chronic inflammatory demyelinating polyneuropathy.  Arch Neurol. 2003;  60 1755-1759
• 30 Van den Bergh P Y, Pieret F. Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy.  Muscle Nerve. 2004;  29 565-574
• 31 Rajabally Y A, Jacob S, Hbahbih M. Optimizing the use of electrophysiology in the diagnosis of chronic inflammatory demyelinating polyneuropathy: a study of 20 cases.  J Peripher Nerv Syst. 2005;  10 282-292
• 32 Rotta F T, Sussman A T, Bradley W G, Ayyar D R, Sharma K R, Shebert R T. The spectrum of chronic inflammatory demyelinating polyneuropathy.  J Neurol Sci. 2000;  173 129-139
• 33 Saperstein D S, Katz J S, Amato A A, Barohn R J. Clinical spectrum of chronic acquired demyelinating polyneuropathies.  Muscle Nerve. 2001;  24 311-324
• 34 Nicolas G, Maisonobe T, Le Forestier N, Leger J M, Bouche P. Proposed revised electrophysiological criteria for chronic inflammatory demyelinating polyradiculoneuropathy.  Muscle Nerve. 2002;  25 26-30
• 35 Hughes R, Bensa S, Willison H et al.. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy.  Ann Neurol. 2001;  50 195-201
• 36 Oh S J, Kim D E, Koruoglu A R. What is the best diagnostic index of conduction block and temporal dispersion.  Muscle Nerve. 1994;  17 489-493
• 37 Dyck P J, O'Brien P C, Oviatt K F et al.. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment.  Ann Neurol. 1982;  11 136-141
• 38 Dyck P J, Daube J, O'Brien P et al.. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy.  N Engl J Med. 1986;  314 461-465
• 39 Hahn A F, Bolton C F, Pillay N et al.. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy: a double-blind, sham-controlled, cross-over study.  Brain. 1996;  119 1055-1066
• 40 Hahn A F, Bolton C F, Zochodne D, Feasby T E. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, cross-over study.  Brain. 1996;  119 1067-1077
• 41 Mendell J R, Barohn R J, Freimer M L et al.. Working Group on Peripheral Neuropathy: randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy.  Neurology. 2001;  56 445-449
• 42 Lopate G, Pestronk A, Al-Lozi M. Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone.  Arch Neurol. 2005;  62 249-254
• 43 van Doorn P A, Dippel D WJ, van Burken M MG et al.. Longterm IV Immunoglobulin Treatment in CIDP.  J Peripher Nerv Syst. 2003;  8(suppl 1) 70-71
• 44 Venance S L, Koopman W J, Hahn A F. Treatment approaches and long-term outcome in a Canadian Cohort (1972-2002) with chronic inflammatory demyelinating polyneuropathy (CIDP).  J Peripher Nerv Syst. 2003;  8 71
• 45 Dyck P J, O'Brien P C, Swanson C et al.. Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy.  Neurology. 1985;  35 1173-1176
• 46 Hodgkinson S J, Pollard J D, McLeod J G. Cyclosporine A in the treatment of chronic demyelinating polyradiculopathy.  J Neurol Neurosurg Psychiatry. 1990;  53 327-330
• 47 Barnett M H, Pollard J D, Davies L, McLeod J G. Cyclosporin A in resistant chronic inflammatory demyelinating polyradiculoneuropathy.  Muscle Nerve. 1998;  21(4) 454-460
• 48 Koski C L. Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy: pathogenesis and treatment.  Semin Neurol. 1994;  14 123-130
• 49 Good J L, Chehrenama M, Mayer R F, Koski C L. Pulsed cyclophosphamide in chronic inflammatory demyelinating polyneuropathy.  Neurology. 1998;  51 1735-1738
• 50 Brannagan T H, Pradham A, Heiman-Patterson T et al.. High-dose cyclophosphamide without stem-cell rescue for refractory CIDP.  Neurology. 2002;  58 1856-1858
• 51 Chaudhry V, Cornblath D R, Griffin J W, O'Brien R, Drachman D B. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases.  Neurology. 2001;  56 94-96
• 52 Mowzoon N, Sussman A, Bradley W G. Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis.  J Neurol Sci. 2001;  185(2) 119-122
• 53 Gorson K C, Amato A A, Ropper A H. Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy.  Neurology. 2004;  63 715-717
• 54 Sabatelli M, Mignona T, Lippi G, Milone M, Lazzaro V D, Tonali P. Interferon-alpha may benefit steroid unresponsive chronic inflammatory demyelinating polyneuropathy.  J Neurol Neurosurg Psychiatry. 1995;  58 638-639
• 55 Choudhary P P, Thompson N, Hughes R AC. Improvement following interferon beta in chronic inflammatory demyelinating polyradiculoneuropathy.  J Neurol. 1995;  242 252-253
• 56 Gorson K C, Ropper A H, Clark B D, Dew R B, Simovic D, Allam G. Treatment of chronic inflammatory demyelinating polyneuropathy with interferon alpha 2a.  Neurology. 1998;  50 84-87
• 57 Hadden R DM, Sharrack B, Bensa S, Soudain S E, Hughes R AC. Randomized trial of interferon B-1a in chronic inflammatory demyelinating polyradiculoneuropathy.  Neurology. 1999;  53 57-61
• 58 Kuntzer T, Radziwill A J, Lettry-Trouillat R et al.. Interferon-B1a in chronic inflammatory demyelinating polyneuropathy.  Neurology. 1999;  53 1364-1365
• 59 Pavesi G, Cattaneo L, Marbini A, Gemignani F, Mancia D. Long-term efficacy of interferon-alpha in chronic inflammatory demyelinating neuropathy.  J Neurol. 2002;  249 777-779
• 60 Vallat J M, Hahn A F, Leger J M et al.. Interferon beta 1a as an investigational treatment for CIDP.  Neurology. 2003;  60(S3) S23-S28
• 61 Fialho D, Chan Y C, Allen D C, Reilly M M, Hughes R A. Treatment of chronic inflammatory demyelinating polyradiculoneuropathy with methotrexate.  J Neurol Neurosurg Psychiatry. 2006;  77 544-547
• 62 Amato A A, Barohn R J, Sahenk Z, Tushka P J, Mendell J R. Polyneuropathy complicating bone marrow transplantation.  Neurology. 1993;  43 1513-1518
• 63 Rechthand E, Cornblath D R, Stern B J, Meyerhoff J O. Chronic demyelinating polyneuropathy in systemic lupus erythematosus.  Neurology. 1984;  34 1375-1377
• 64 Romanick-Schmiedl S, Kiprov D D, Chalmers A C, Miller R G. Extraneural manifestations of chronic inflammatory demyelinating polyradiculoneuropathy.  Am J Med. 1990;  89 531-534
• 65 Stewart J D, McKelvey R, Durcan L, Carpenter S, Karpati G. Chronic inflammatory demyelinating polyneuropathy (CIDP) in diabetics.  J Neurol Sci. 1996;  142 59-64
• 66 Taylor B V, Wijdicks E FM, Poterucha J J, Weinser R H. Chronic inflammatory demyelinating polyneuropathy complicating liver transplantation.  Ann Neurol. 1995;  38 828-831
• 67 Dyck P J, Swanson C J, Low P A, Bartleson J D, Lambert E H. Prednisone-responsive hereditary motor and sensory neuropathy.  Mayo Clin Proc. 1982;  57 239-246
• 68 Sharma K R, Cross J, Farronay O, Ayyar D R, Shebert R T, Bradley W G. Demyelinating neuropathy in diabetes mellitus.  Arch Neurol. 2002;  59 758-765
• 69 Gorson K C, Ropper A H, Adelman L S, Weinberg D H. Influence of diabetes mellitus on chronic inflammatory demyelinating polyneuropathy.  Muscle Nerve. 2000;  23 37-43
• 70 Sharma K R, Cross J, Ayyar D R, Martinez-Arizala A, Bradley W G. Diabetic demyelinating polyneuropathy responsive to intravenous immunoglobulin therapy.  Arch Neurol. 2002;  59 751-757
• 71 Wilson J R, Park Y, Fisher M R. Electrodiagnostic criteria in CIDP: comparison with diabetic neuropathy.  Electromyogr Clin Neurophysiol. 2000;  40 181-185
• 72 Barohn R J, Sahenk Z, Warmolts J R, Mendell J R. The Bruns-Garland syndrome (diabetic amyotrophy). Revisited 100 years later.  Arch Neurol. 1991;  48 1130-1135
• 73 Abu-Shakra S R, Cornblath D R, Avila O L et al.. Conduction block in diabetic neuropathy.  Muscle Nerve. 1991;  14 858-862
• 74 Tan E, Hajinazarian M, Bay W, Neff J, Mendell J R. Acute renal failure resulting from intravenous immunoglobulin therapy.  Arch Neurol. 1993;  50 137-139
• 75 Kissel J T, Mendell J R. Neuropathies associated with monoclonal proteins.  Neuromuscul Disord. 1996;  6 3-18
• 76 Kyle R A, Dyck P J. Neuropathy associated with the monoclonal gammopathies. In: Dyck PJ, Thomas PK, Griffin JW, Low PA, Podulso JF Peripheral Neuropathy. 3rd ed. Philadelphia; WB Saunders 1993: 1275-1287
• 77 Simmons Z, Albers J W, Bromberg M B, Feldman E L. Presentation and initial clinical course in patients with chronic inflammatory demyelinating polyradiculoneuropathy: comparison of patients without and with monoclonal gammopathy.  Neurology. 1993;  43 2202-2209
• 78 Nobile-Orazio E, Manfredini E, Carpo M et al.. Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy.  Ann Neurol. 1994;  36 416-424
• 79 Notermans N C, Franssen H, Eurerlings M, Van der Graaf Y, Wokke J HJ. Diagnostic criteria for demyelinating polyneuropathy associated with monoclonal gammopathy.  Muscle Nerve. 2000;  23 73-79
• 80 Smith I S. The natural history of chronic demyelinating neuropathy associated with benign IgM paraproteinaemia. A clinical and neurophysiological study.  Brain. 1994;  117 949-957
• 81 Suarez G A, Kelly Jr J J. Polyneuropathy associated with monoclonal gammopathy of undetermined significance: further evidence that IgM-MGUS neuropathies are different than IgG-MGUS.  Neurology. 1993;  43 1304-1308
• 82 Dalakas M C, Teravainen J, Engel W K. Tremor as a feature of chronic relapsing and dysgammaglobulinemic polyneuropathies. Incidence and management.  Arch Neurol. 1984;  41 711-714
• 83 Yeung K B, Thomas P K, King R H et al.. The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia. Comparative clinical, immunological and nerve biopsy findings.  J Neurol. 1991;  238 383-391
• 84 Chassande B, Leger J M, Younes-Chennoufi A B et al.. Peripheral neuropathy associated with IgM monoclonal gammopathy: correlations between M-protein antibody activity and clinical/electrophysiological features in 40 cases.  Muscle Nerve. 1998;  21 55-62
• 85 Kelly J J, Adelman L S, Berkman E, Bhan I. Polyneuropathies associated with IgM monoclonal gammopathies.  Arch Neurol. 1988;  45 1355-1359
• 86 Latov N, Hays A P, Sherman W H. Peripheral neuropathy and anti-MAG antibodies.  Crit Rev Neurobiol. 1988;  3 301-332
• 87 Gosselin S, Kyle R A, Dyck P J. Neuropathy associated with monoclonal gammopathies of undetermined significance.  Ann Neurol. 1991;  30 54-61
• 88 Simovic D, Gorson K C, Ropper A H. Comparison of IgM-MGUS and IgG-MGUS polyneuropathy.  Acta Neurol Scand. 1998;  97 194-200
• 89 Kaku D A, England J D, Sumner A J. Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside.  Brain. 1994;  117 941-947
• 90 Trojaborg W, Hays A P, van den B L, Younger D S, Latov N. Motor conduction parameters in neuropathies associated with anti-MAG antibodies and other types of demyelinating and axonal neuropathies.  Muscle Nerve. 1995;  18 730-735
• 91 Di Troia A, Carpo M, Meucci N et al.. Clinical features and anti-neural reactivity in neuropathy with IgG monoclonal gammopathy of undetermined significance.  J Neurol Sci. 1999;  164 64-71
• 92 Dyck P J, Low P A, Windebank A J et al.. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance.  N Engl J Med. 1991;  325 1482-1486
• 93 Nobile-Orazio E, Meucci N, Baldini L, Di Troia A, Scarlato G. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies.  Brain. 2000;  123 710-717
• 94 Pollard J D, Young G AR. Neurology and the bone marrow.  J Neurol Neurosurg Psychiatry. 1997;  63 706-718
• 95 Dalakas M C, Quarles R H, Farrer R G et al.. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy.  Ann Neurol. 1996;  40 792-795
• 96 Mariette X, Leger J M, Chevret S et al.. A randomized double-blind trial versus placebo does not confirm the efficacy of alpha-interferon in polyneuropathy associated with anti-MAG IgM monoclonal gammopathy.  Neurology. 2000;  54(suppl 3) A213
• 97 Mariette X, Chastang C, Clavelou P, Louboutin J P, Leger J M, Brouet J C. A randomised clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM-associated Polyneuropathy Study Group.  J Neurol Neurosurg Psychiatry. 1997;  63 28-34
• 98 Blume G, Pestronk A, Goodnough L T. Anti-MAG antibody-associated polyneuropathies: Improvement following immunotherapy with monthly plasma exchange and IV cyclophosphamide.  Neurology. 1995;  45 1577-1580
• 99 Ellie E, Vital A, Steck A, Boiron J M, Vital C, Julien J. Neuropathy associated with “benign” anti-myelin-associated glycoprotein IgM gammopathy: clinical, immunological, neurophysiological pathological findings and response to treatment in 33 cases.  J Neurol. 1996;  243 34-43
• 100 Ernerudh J, Brodtkorb E, Olsson T, Vedeler C A, Nyland H, Berlin G. Peripheral neuropathy and monoclonal IgM with antibody activity against peripheral nerve myelin; effect of plasma exchange.  J Neuroimmunol. 1986;  11 171-178
• 101 Haas D C, Tatum A H. Plasmapheresis alleviates neuropathy accompanying IgM anti-myelin-associated glycoprotein paraproteinemia.  Ann Neurol. 1988;  23 394-396
• 102 Kelly J J, Adelman L S, Berkman E, Bhan I. Polyneuropathies associated with IgM monoclonal gammopathies.  Arch Neurol. 1988;  45 1355-1359
• 103 Levine T D, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab.  Neurology. 1999;  52 1701-1704
• 104 Nobile-Orazio E, Baldini L, Barbieri S et al.. Treatment of patients with neuropathy and anti-MAG IgM M-proteins.  Ann Neurol. 1988;  24 93-97
• 105 Notermans N C, Lokhorst H M, Franssen H et al.. Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance.  Neurology. 1996;  47 1227-1233
• 106 Oksenhendler E, Chevret S, Léger J M, Louboutin J P, Bussel A, Brouet J C. Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM-associated Polyneuropathy Study Group.  J Neurol Neurosurg Psychiatry. 1995;  59 243-247
• 107 Smith T, Sherman W, Olarte M R, Lovelace R E. Peripheral neuropathy associated with plasma cell dyscrasia: a clinical and electrophysiological follow-up study.  Acta Neurol Scand. 1987;  75 244-248
• 108 Wilson H C, Lunn M P, Schey S, Hughes R A. Successful treatment of IgM paraproteinaemic neuropathy with fludarabine.  J Neurol Neurosurg Psychiatry. 1999;  66 575-580
• 109 Levine T D, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab.  Neurology. 1999;  52 1701-1704
• 110 Pestronk A, Florence J, Miller T, Choksi R, Al-Lozi M T, Levine T D. Treatment of IgM antibody associated polyneuropathies using rituximab.  J Neurol Neurosurg Psychiatry. 2003;  74 485-489
• 111 Renaud S, Gregor M, Fuhr P et al.. Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies.  Muscle Nerve. 2003;  27 611-615
• 112 Renaud S, Fuhr P, Gregor M et al.. High-dose rituximab and anti-MAG-associated polyneuropathy.  Neurology. 2006;  66 742-744
• 113 Barohn R J, Rashid I, McVey A L, Herbelin L, Skikne B, Saperstein D S. Rituximab for the treatment of IgM-associated polyneuropathies.  J Peripher Nerv Syst. 2005;  10(suppl 1) 4
• 114 Joint Task Force of the EFNS and the PNS . European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society.  J Peripher Nerv Syst. 2006;  11 9-19
• 115 Oh S J, Joy J L, Kuruoglu R. “Chronic sensory demyelinating neuropathy”: chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy.  J Neurol Neurosurg Psychiatry. 1992;  55 677-680
• 116 Oh S J, Joy J L, Sunwoo I, Kuruoglu R. A case of chronic sensory demyelinating neuropathy responding to immunotherapies.  Muscle Nerve. 1992;  15 255-256
• 117 Simmons Z, Tivakaran S. Acquired demyelinating polyneuropathy presenting as a pure clinical sensory syndrome.  Muscle Nerve. 1996;  19 1174-1176
• 118 Parry G J, Clarke S. Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease.  Muscle Nerve. 1988;  11 103-107
• 119 Chad D A, Hammer K, Sargent J. Slow resolution of multifocal weakness and fasciculation: a reversible motor neuron syndrome.  Neurology. 1986;  36 1260-1263
• 120 Kaji R, Shibasaki H, Kimura J. Multifocal demyelinating motor neuropathy: cranial nerve involvement and immunoglobulin therapy.  Neurology. 1992;  42 506-509
• 121 Krarup C, Stewart J D, Sumner A J, Pestronk A, Lipton S A. A syndrome of asymmetric limb weakness with motor conduction block.  Neurology. 1990;  40 118-127
• 122 Pestronk A, Cornblath D R, Ilyas A A et al.. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside.  Ann Neurol. 1988;  24 73-78
• 123 Roth G, Rohr J, Magistris M R, Ochsner F. Motor neuropathy with proximal multifocal persistent conduction block, fasciculations and myokymia. Evolution to tetraplegia.  Eur Neurol. 1986;  25 416-423
• 124 Katz J S, Wolfe G I, Bryan W W, Jackson C E, Amato A A, Barohn R J. Electrophysiologic findings in multifocal motor neuropathy.  Neurology. 1997;  48 700-707
• 125 Azulay J P, Attarian S, Pouget J. Effect of cyclophosphamide in multifocal motor neuropathies with or without conduction block.  Neurology. 1999;  52(suppl 2) A550-A551
• 126 Ellis C M, Leary S, Shaw J, Hu C, O'Brien M, Leigh P N. Use of human intravenous immunoglobulin in lower motor neuron syndromes.  J Neurol Neurosurg Psychiatry. 1999;  67 15-19
• 127 Pakiam A S, Parry G J. Multifocal motor neuropathy without overt conduction block.  Muscle Nerve. 1998;  21 243-245
• 128 Auer R N, Bell R B, Lee M A. Neuropathy with onion bulb formations and pure motor manifestations.  Can J Neurol Sci. 1989;  16 194-197
• 129 Chaudhry V. Multifocal motor neuropathy.  Semin Neurol. 1998;  18 73-81
• 130 Chaudhry V, Corse A M, Cornblath D R et al.. Multifocal motor neuropathy: response to human immune globulin.  Ann Neurol. 1993;  33 237-242
• 131 Chaudhry V, Corse A M, Cornblath D R, Kuncl R W, Freimer M L, Griffin J W. Multifocal motor neuropathy: electrodiagnostic features.  Muscle Nerve. 1994;  17 198-205
• 132 Feldman E L, Bromberg M B, Albers J W, Pestronk A. Immunosuppressive treatment in multifocal motor neuropathy.  Ann Neurol. 1991;  30 397-401
• 133 Parry G J, Sumner A J. Multifocal motor neuropathy.  Neurol Clin. 1992;  10 671-684
• 134 Joint Task Force of the EFNS and the PNS . European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society.  J Peripher Nerv Syst. 2006;  11 1-8
• 135 Kaji R, Hirota N, Oka N et al.. Anti-GM1 antibodies and impaired blood-nerve barrier may interfere with remyelination in multifocal motor neuropathy.  Muscle Nerve. 1994;  17 108-110
• 136 Kornberg A J, Pestronk A. The clinical and diagnostic role of anti-GM1 antibody testing.  Muscle Nerve. 1994;  17 100-104
• 137 Lange D J, Trojaborg W, Latov N et al.. Multifocal motor neuropathy with conduction block: is it a distinct clinical entity?.  Neurology. 1992;  42 497-505
• 138 Parry G J. Antiganglioside antibodies do not necessarily play a role in multifocal motor neuropathy.  Muscle Nerve. 1994;  17 97-99
• 139 Sadiq S A, Thomas F P, Kilidireas K et al.. The spectrum of neurologic disease associated with anti-GM1 antibodies.  Neurology. 1990;  40 1067-1072
• 140 Tan E, Lynn D J, Amato A A et al.. Immunosuppressive treatment of motor neuron syndromes. Attempts to distinguish a treatable disorder.  Arch Neurol. 1994;  51 194-200
• 141 Taylor B V, Gross L, Windebank A J. The sensitivity and specificity of anti-GM1 antibody testing.  Neurology. 1996;  47 951-955
• 142 van Schaik I N, Bossuyt P MM, Brand A, Vermeulen M. Diagnostic value of GM1 antibodies in motor neuron disorders and neuropathies: a meta-analysis.  Neurology. 1995;  45 1570-1577
• 143 Pestronk A, Chaudhry V, Feldman E L et al.. Lower motor neuron syndromes defined by patterns of weakness, nerve conduction abnormalities, and high titers of antiglycolipid antibodies.  Ann Neurol. 1990;  27 316-326
• 144 Pestronk A, Choksi R. Multifocal motor neuropathy. Serum IgM anti-GM1 ganglioside antibodies in most patients detected using covalent linkage of GM1 to ELISA plates.  Neurology. 1997;  49 1289-1292
• 145 Carpo M, Allaria S, Scarlato G, Nobile-Orazio E. Marginally improved detection of GM1 antibodies by Covalink ELISA in multifocal motor neuropathy.  Neurology. 1999;  53 2206-2207
• 146 Comi G, Amadio S, Galardi G, Fazio R, Nemni R. Clinical and neurophysiological assessment of immunoglobulin therapy in five patients with multifocal motor neuropathy.  J Neurol Neurosurg Psychiatry. 1994;  57(suppl) 35-37
• 147 Weimer L H, Grewal R P, Lange D J. Electrophysiologic abnormalities other than conduction block in multifocal motor neuropathy.  Muscle Nerve. 1994;  9 1089
• 148 Nobile-Orazio E, Meucci N, Carpo M et al.. Multifocal motor neuropathy: comparison of clinical and immunological features and response to IVIg in patients with and without overt conduction block.  Neurology. 2000;  54(suppl 3) A369-A370
• 149 Bouche P, Moulonguet A, Younes-Chennoufi A B et al.. Multifocal motor neuropathy with conduction block: a study of 24 patients.  J Neurol Neurosurg Psychiatry. 1995;  59 38-44
• 150 Corse A M, Chaudhry V, Crawford T O, Cornblath D R, Kuncl R W, Griffin J W. Sensory nerve pathology in multifocal motor neuropathy.  Ann Neurol. 1996;  39 319-325
• 151 Van Es H W, Van den Berg L H, Franssen H et al.. Magnetic resonance imaging of the brachial plexus in patients with multifocal motor neuropathy.  Neurology. 1997;  48 1218-1224
• 152 Van den Berg-Vos R M, Van den Berg L H, Franssen H et al.. Multifocal inflammatory demyelinating neuropathy: a distinct clinical entity?.  Neurology. 2000;  54 26-32
• 153 Charles N, Benoit P, Vial C, Bierme T, Moreau T, Bady B. Intravenous immunoglobulin treatment in multifocal motor neuropathy.  Lancet. 1992;  340 182
• 154 Donaghy M, Mills K R, Boniface S J et al.. Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin.  J Neurol Neurosurg Psychiatry. 1994;  57 778-783
• 155 Olney R K, Pestronk A. Prednisone treatment of multifocal motor neuropathy.  Neurology. 1992;  42(suppl 3) 178
• 156 Carpo M, Cappellari A, Mora G et al.. Deterioration of multifocal motor neuropathy after plasma exchange.  Neurology. 1998;  50 1480-1482
• 157 Cruz Martinez A, Arpa J, Lara M. Electrophysiological improvement after intravenous immunoglobulin in motor neuropathy with multifocal conduction block.  J Neurol Neurosurg Psychiatry. 1993;  56 1236-1237
• 158 Markson L, Janzen D, Bril V. Response to therapy in demyelinating motor neuropathy.  Muscle Nerve. 1998;  21 1769-1771
• 159 Azulay J P, Blin O, Pouget J et al.. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study.  Neurology. 1994;  44 429-432
• 160 Van den Berg L H, Kerkhoff H, Oey P L et al.. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study.  J Neurol Neurosurg Psychiatry. 1995;  59 248-252
• 161 Chaudhry V, Corse A, Cornblath D et al.. Maintenance immune globulin therapy for multifocal motor neuropathy: results of long-term follow-up.  Ann Neurol. 1996;  40 513-514
• 162 Azulay J P, Rihet P, Pouget J et al.. Long term follow up of multifocal motor neuropathy with conduction block under treatment.  J Neurol Neurosurg Psychiatry. 1997;  62 391-394
• 163 Biessels G J, Franssen H, Van den Berg L H et al.. Multifocal motor neuropathy.  J Neurol. 1997;  244 143-152
• 164 Taylor B V, Wright R A, Harper C M, Dyck P J. Natural history of 46 patients with multifocal motor neuropathy with conduction block.  Muscle Nerve. 2000;  23 900-908
• 165 Martina I S, van Doorn P A, Schmitz P I, Meulstee J, van der Meche F G. Chronic motor neuropathies: response to interferon-beta1a after failure of conventional therapies.  J Neurol Neurosurg Psychiatry. 1999;  66 197-201
• 166 Van den Berg-Vos R M, Van den Berg L H, Franssen H, van Doorn P A, Merkies I SJ, Wokke J H. Treatment of multifocal motor neuropathy with interferon beta-1A.  Neurology. 2000;  54 1518-1521
• 167 Ruegg S J, Fuhr P, Steck A J. Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg.  Neurology. 2004;  63 2178-2179
• 168 Lewis R A, Sumner A J, Brown M J, Asbury A K. Multifocal demyelinating neuropathy with persistent conduction block.  Neurology. 1982;  32 958-964
• 169 Oh S J, Claussen G C, Kim D S. Motor and sensory demyelinating mononeuropathy multiplex (multifocal motor and sensory demyelinating neuropathy): a separate variant of chronic inflammatory demyelinating polyneuropathy.  J Periph Nerv Syst. 1997;  2 362-369
• 170 Saperstein D S, Amato A A, Wolfe G I et al.. Multifocal acquired demyelinating sensory and motor neuropathy: the Lewis-Sumner syndrome.  Muscle Nerve. 1999;  22 560-566
• 171 Gorson K C, Ropper A H, Weinberg D H. Upper limb predominant, multifocal chronic inflammatory demyelinating polyneuropathy.  Muscle Nerve. 1999;  22 758-765
• 172 Thomas P K, Claus D, Jaspert A et al.. Focal upper limb demyelinating neuropathy.  Brain. 1996;  119 765-774
• 173 Lewis R A. Multifocal motor neuropathy and Lewis-Sumner syndrome: two distinct entities.  Muscle Nerve. 1999;  22 1738-1739
• 174 Parry G J. Are multifocal motor neuropathy and Lewis-Sumner syndrome distinct nosologic entities?.  Muscle Nerve. 1999;  22 557-559
• 175 Amato A A, Jackson C E, Kim J Y, Worley K L. Chronic relapsing brachial plexus neuropathy with persistent conduction block.  Muscle Nerve. 1997;  20 1303-1307
• 176 Gibbels E, Behse F, Kentenich M, Haupt W F. Chronic multifocal neuropathy with persistent conduction block (Lewis-Sumner syndrome). A clinico-morphologic study of two further cases with review of the literature.  Clin Neuropathol. 1993;  12 343-352
• 177 Nascimento O JM, de Freitas R G, Hahn M. Multifocal motor and sensory demyelinating neuropathy (MMSDN): a probable distinct condition from multifocal motor neuropathy (MMN).  J Neurol. 1999;  246(suppl 1) 115
• 178 Nukada H, Pollock M, Haas L F. Is ischemia implicated in chronic multifocal demyelinating neuropathy?.  Neurology. 1989;  39 106-110
• 179 Olney R K. American Association of Electrodiagnostic Medicine . Guidelines in electrodiagnostic medicine. Consensus criteria for the diagnosis of partial conduction block.  Muscle Nerve Suppl. 1999;  8 S225-S229
• 180 Saperstein D S, Alseoudi S, Anderson H, Herbelin L, McVey A L, Barohn R J. The effect of combining clinical and electrodiagnostic data on the sensitivity of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy [abstract].  J Peripher Nerv Syst. 2007;  12(suppl 1) 75-76